drugset / Trial / NCT01646489

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

NCT01646489

Phase 1 Completed 5 enrolled Santaris Pharma A/S
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and affect on blood levels of miravirsen and telaprevir when administered together.

Timeline

Start
2012-06
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Miravirsen Antisense oligonucleotide 7 mg/kg Subcutaneous
Comparator Telaprevir Small molecule 750 mg Oral